Literature DB >> 8395116

Pyvs: a dominantly acting gene in C3H/BiDa mice conferring susceptibility to tumor induction by polyoma virus.

A E Lukacher1, R Freund, J P Carroll, R T Bronson, T L Benjamin.   

Abstract

Results in a previous report established the presence of dominant genetic factor(s) in C3H/BiDa mice which contributed to the unusually high susceptibility of this strain to polyoma virus-induced tumors (Freund et al. (1992) Virology 191, 724-731). Here we show that C57BR/cdJ mice, while identical to C3H/BiDa at the H-2 locus, are almost completely lacking in susceptibility. Analysis of crosses between these two H-2k strains has shown that susceptibility is due to a single dominant autosomal gene, designated Pyvs. On an H-2k background, Pyvs acts in a highly penetrant manner to confer susceptibility to induction of a broad range of tumors by the virus. Analysis of F1 mice between C3H/BiDa and the highly resistant C57BL/6 (H-2b) strain shows that Pyvs can partially overcome the immunologically mediated resistance associated with an H-2b haplotype. Pyvs does not encode cell receptors for the virus, nor does it affect levels of virus replication or anti-viral humoral responses in the host. Studies with early passage embryo fibroblasts in culture show that Pyvs does not affect intracellular events essential for either productive infection or cell transformation by the virus. Pyvs thus determines a generalized susceptibility of the host to polyoma-induced tumors but apparently does not act at the level of target cells for tumor induction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395116     DOI: 10.1006/viro.1993.1472

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

Review 1.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

2.  Abl family tyrosine kinases regulate sialylated ganglioside receptors for polyomavirus.

Authors:  Alyson I Swimm; William Bornmann; Mengxi Jiang; Michael J Imperiale; Aron E Lukacher; Daniel Kalman
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

3.  Wild-derived inbred mice have a novel basis of susceptibility to polyomavirus-induced tumors.

Authors:  P Velupillai; I Yoshizawa; D C Dey; S R Nahill; J P Carroll; R T Bronson; T L Benjamin
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  Polymorphisms in toll-like receptor 4 underlie susceptibility to tumor induction by the mouse polyomavirus.

Authors:  Palanivel Velupillai; Chang Kyoo Sung; Erik Andrews; Jennifer Moran; David Beier; Jonathan Kagan; Thomas Benjamin
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

5.  Identification of TAZ as a binding partner of the polyomavirus T antigens.

Authors:  Yu Tian; Dawei Li; Jean Dahl; John You; Thomas Benjamin
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Polyomavirus-infected dendritic cells induce antiviral CD8(+) T lymphocytes.

Authors:  D R Drake; J M Moser; A Hadley; J D Altman; C Maliszewski; E Butz; A E Lukacher
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Radiation-resistant and radiation-sensitive forms of host resistance to polyomavirus.

Authors:  J P Carroll; J S Fung; R T Bronson; E Razvi; T L Benjamin
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Generation of antiviral major histocompatibility complex class I-restricted T cells in the absence of CD8 coreceptors.

Authors:  Nicolas P Andrews; Christopher D Pack; Aron E Lukacher
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

Review 9.  Pathogen-host standoff: immunity to polyomavirus infection and neoplasia.

Authors:  Aron E Lukacher
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 10.  Immunity to polyomavirus infection: the polyomavirus-mouse model.

Authors:  Phillip A Swanson; Aron E Lukacher; Eva Szomolanyi-Tsuda
Journal:  Semin Cancer Biol       Date:  2009-02-14       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.